References
- ChungMKozuchPTreatment of malignant ascitesCurr Treat Options Oncol20089221523318777213
- FlemingNDAlvarez-SecordAVon GruenigenVMillerMJAbernethyAPIndwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart reviewJ Pain Symptom Manage200938334134919328648
- BeckerGMedical and palliative management of malignant ascitesCancer Treat Res200713445946717633074
- ShenJZhuZCatumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancerCurr Opin Mol Ther200810327328418535935
- AyantundeAAParsonsSLPattern and prognostic factors in patients with malignant ascites: a retrospective studyAnn Oncol200718594594917298959
- GarrisonRNGallowayRHHeuserLSMechanisms of malignant ascites productionJ Surg Res19874221262434730
- ZebrowskiBKLiuWRamirezKMarkedly elevated levels of vascular endothelial growth factor in malignant ascitesAnn Surg Oncol19996437337810379858
- FanLYIsekiSImmunohistochemical localization of vascular endothelial growth factor in the globule leukocyte/mucosal mast cell of the rat respiratory and digestive tractsHistochem Cell Biol1999111113219930879
- KraftAWeindelKOchsAVascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant diseaseCancer19998511781879921991
- GarrisonRNKaelinLDGallowayRHHeuserLSMalignant ascites. Clinical and experimental observationsAnn Surg198620366443718029
- MasabumiSMasashiTSachikoYInvolvement of VEGF and its receptors in ascites tumor formationCancer Chemother Pharmacol1999430S72S7710357563
- LissoniPRovelliFMaluganiFChanges in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancerThe Int J Biol Markers2003182152155
- ParsonsSLWatsonSASteeleRJCMalignant ascitesBr J Surg19968316148653366
- BeattieGJSmythJFPhase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascitesClin Cancer Res199848189919029717817
- FerrellBSmithSLCullinaneCAMelanconCPsychological well being and quality of life in ovarian cancer survivorsCancer20039851061107112942576
- CattauELJrBenjaminSBKnuffTECastellDOThe accuracy of the physical examination in the diagnosis of suspected ascitesJAMA1982247811647057606
- InadomiJCelloJPKochJUltrasonographic determination of ascitic volumeHepatology19962435495518781322
- WalkeyMMFriedmanACSohotraPRadeckiPDCT manifestations of peritoneal carcinomatosisAm J Roentgenol19881505103510413258703
- AkriviadisEAHemoperitoneum in patients with ascitesAm J Gastroenterol19979245679128301
- PressOWPressNOKaufmanSDEvaluation and management of chylous ascitesAnn Intern Med19829633587059101
- RunyonBAMontanoAAAkriviadisEAThe serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascitesAnn Intern Med199211732151616215
- CardozoPLA critical evaluation of 3,000 cytologic analyses of pleural fluid, ascitic fluid and pericardial fluidActa Cytol196610455460
- LoewensteinMSRittgersRAFeinermanAECarcinoembryonic antigen assay of ascites and detection of malignancyAnn Intern Med1978885635646247
- ParsonsSLLangMWSteeleRJCMalignant ascites: a 2-year review from a teaching hospitalEur J Surg Oncol19962232372398654603
- MackeyJRVennerPMMalignant ascites: demographics, therapeutic efficacy and predictors of survivalCan J Oncol19966247448012056099
- BeckerGGalandiDBlumHEMalignant ascites: systematic review and guideline for treatmentEur J Cancer200642558959716434188
- McNamaraPParacentesis – an effective method of symptom control in the palliative care setting?Palliat Med2000141626410717726
- StephensonJGilbertJThe development of clinical guidelines on paracentesis for ascites related to malignancyPalliat Med200216321312046997
- RunyonBAManagement of adult patients with ascites caused by cirrhosisHepatology19982712642729425946
- SalernoFBadalamentiSIncertiPRepeated paracentesis and iv albumin infusion to treat ‘tense’ ascites in cirrhotic patients: a safe alternative therapyJ Hepatol1987511023655306
- GinesPTitoELArroyoVRandomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosisGastroenterology198894614933360270
- GotliebWHFeldmanBFeldman-MoranOIntraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancerGynecol Oncol19987133813859887235
- LeeCWBociekGFaughtWA survey of practice in management of malignant ascitesJ Pain Symptom Manage1998162961019737100
- PockrosPJEsrasonKTNguyenCDuqueJWoodsSMobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristicsGastroenterology19921034130213061397889
- GreenwayBJohnsonPJWilliamsRControl of malignant ascites with spironolactoneBr J Surg19826984414427049306
- SharmaSWalshDManagement of symptomatic malignant ascites with diuretics: two case reports and a review of the literatureJ Pain Symptom Manage19951032372427629417
- GoughIRBaldersonGAMalignant ascites. A comparison of peritoneovenous shunting and nonoperative managementCA Cancer J Clin199371723772382
- LeVeenHHWapnickSGrosbergSKinneyMJFurther experience with peritoneo-venous shunt for ascitesAnnals Surg19761845574
- QaziRSavlovEDPeritoneovenous shunt for palliation of malignant ascitesCA Cancer J Clin1982493600602
- EdneyJAHillAArmstrongDPeritoneovenous shunts palliate malignant ascitesAm J Surg198915865982480068
- SmithDAWeaverDWBouwmanDLPeritoneovenous shunt (PVS) for malignant ascites: an analysis of outcomeAm Surgeon19895574452742227
- CheungDKRaafJHSelection of patients with malignant ascites for a peritoneovenous shuntCA Cancer J Clin198250612041209
- SmithEMJaysonGCThe current and future management of malignant ascitesClin Oncol (R Coll Radiol)2003152597212708713
- AdamRAAdamYGMalignant ascites: past, present, and futureJ Am Coll Surg20041986999101115194082
- OzkanOAkinciDGocmenRCilBOzmenMAkhanOPercutaneous placement of peritoneal port-catheter in patients with malignant ascitesCardiovasc Intervent Radiol200730223223617206391
- BrooksRAHerzogTJLong-term semi-permanent catheter use for the palliation of malignant ascitesGynecol Oncol2006101236036216499957
- RosenbergSMPalliation of malignant ascitesGastroenterol Clin N2006351189199
- CairnsWMaloneROctreotide as an agent for the relief of malignant ascites in palliative care patientsPalliat Med199913542943010659116
- HuangSRobinsonJBDeguzmanABucanaCDFidlerIJBlockade of nuclear factor κ-B signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8Cancer Res20006019533411034066
- XuLYonedaJHerreraCWoodJKillionJJFidlerIJInhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinasesInt J Oncol200016344545410675474
- BeattieGJSmythJFPhase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascitesClin Cancer Res199848189919029717817
- StuartGCENationJGSniderDDThunbergPIntraperitoneal interferon in the management of malignant ascitesCA Cancer J Clin199371620272030
- EinhornNLingPEinhornSStranderHA phase II study on escalating interferon doses in advanced ovarian carcinomaAm J Clin Oncol198811133277373
- RathUKaufmannMSchmidHEffect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascitesEur J Cancer19912721211827272
- SebastianMKiewePSchuetteWTreatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 studyJ Immunother200932219520219238019
- Revill MelyNBozzoJCatumaxomab Anti-Ep-CAM Monoclonal AntibodyDrugs Future2008335385391
- ZeidlerRReisbachGWollenbergBSimultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killingJ Immunol19991633124610415020
- ZeidlerRMysliwietzJCsanadyMThe Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cellsBr J Cancer200083226126610901380
- StanojeviZRaniGRadiSPathogenesis of malignant ascites in ovarian cancer patientsArchive of Oncology2004122115118
- BurgesAWimbergerPKumperCEffective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II studyClin Cancer Res200713133899390517606723